Letetresgene Autoleucel in Advanced/Metastatic Myxoid/Round Cell Liposarcoma
Researchers conducted a pilot trial of an immune therapy called adoptive T-cell therapy in which immune cells called T-cells are taken from the patient and genes that make receptors that bind to proteins that are specifically expressed on the tumor are delivered to the T-cells, allowing the T cells to attack the tumor. In this case, the new genes code for a receptor that binds to a protein called New York esophageal squamous cell carcinoma 1 (NY-ESO-1) that is expressed on myxoid/round cell liposarcoma (MRCLS).
Patients that undergo adoptive T-cell therapy must undergo a lymphodepletion regimen which prepares the body for receiving modified T-cells. In this study, 10 patients were given a reduced-dose regimen (cohort 1) and 10 patients were given the standard regimen (cohort 2). The primary end point of overall response rate (ORR) was 20% and 40%, the median duration of response was 5.3 months and 7.5 months, and median progression-free survival was 5.4 months and 8.7 months in cohorts 1 and 2, respectively. Further studies need to be conducted, but this study indicates that lete-cel may be a promising treatment for advance metastatic myxoid/round cell liposarcoma.